Medite Cancer Diagnostics, Inc. (CYOE) financial statements (2022 and earlier)
Company profile
| Business Address |
414 NORTH ORLEANS STREET CHICAGO, IL 60610 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Cash and cash equivalents | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Receivables | 0 | 1 | 2 | 2 | 0 | 0 | ||
| Inventory, net of allowances, customer advances and progress billings | 2 | 4 | 3 | 3 | ✕ | ✕ | ||
| Inventory | 2 | 4 | 3 | 3 | ||||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | ✕ | 0 | ||
| Other undisclosed current assets | 1 | 0 | 0 | 0 | 0 | |||
| Total current assets: | 3 | 5 | 6 | 6 | 0 | 0 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 2 | 2 | 2 | 2 | 0 | 0 | ||
| Intangible assets, net (including goodwill) | 5 | 5 | 5 | 2 | ✕ | ✕ | ||
| Goodwill | 5 | 5 | 5 | 2 | ||||
| Other noncurrent assets | 0 | 0 | 0 | 0 | ✕ | |||
| Other undisclosed noncurrent assets | 6 | 6 | 6 | 6 | ||||
| Total noncurrent assets: | 12 | 12 | 13 | 11 | 0 | 0 | ||
| TOTAL ASSETS: | 16 | 18 | 18 | 16 | 0 | 0 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 3 | 3 | 3 | 4 | 5 | 5 | ||
| Accounts payable | 1 | 1 | 0 | 1 | ||||
| Accrued liabilities | 3 | 3 | 3 | 3 | 1 | 1 | ||
| Employee-related liabilities | 1 | 1 | 2 | 3 | 3 | |||
| Taxes payable | 0 | 0 | ||||||
| Interest and dividends payable | 0 | |||||||
| Other undisclosed accounts payable and accrued liabilities | (2) | (2) | (2) | |||||
| Debt | (0) | (3) | (3) | 3 | 0 | 0 | ||
| Due to related parties | 0 | 0 | 0 | 0 | 0 | 3 | ||
| Other undisclosed current liabilities | 0 | 7 | 6 | (0) | (0) | |||
| Total current liabilities: | 4 | 7 | 6 | 7 | 4 | 8 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 5 | 0 | 0 | 1 | ||||
| Long-term debt, excluding current maturities | 5 | 0 | 0 | 1 | ||||
| Liabilities, other than long-term debt | 2 | 2 | 3 | |||||
| Deferred tax liabilities, net | 1 | 2 | 2 | |||||
| Due to related parties | 0 | 0 | 1 | |||||
| Total noncurrent liabilities: | 6 | 2 | 3 | 1 | ||||
| Total liabilities: | 10 | 10 | 9 | 8 | 4 | 8 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 6 | 8 | 9 | 8 | (4) | (7) | ||
| Preferred stock | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Common stock, value, subscriptions | 0 | ✕ | ✕ | |||||
| Additional paid in capital | 14 | 9 | 8 | 6 | 97 | 93 | ||
| Accumulated other comprehensive loss | (0) | (1) | (1) | (0) | ||||
| Retained earnings (accumulated deficit) | (8) | (1) | 1 | 2 | (103) | (102) | ||
| Total stockholders' equity: | 6 | 8 | 9 | 8 | (4) | (7) | ||
| TOTAL LIABILITIES AND EQUITY: | 16 | 18 | 18 | 16 | 0 | 0 | ||
Income statement (P&L) ($ in millions)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 7 | 9 | 10 | 11 | 0 | 0 | |
| Cost of revenue | (7) | (6) | (6) | (7) | (0) | (0) | |
| Gross profit: | 0 | 4 | 4 | 4 | 0 | 0 | |
| Operating expenses | (1) | (2) | (1) | (2) | (1) | (2) | |
| Other undisclosed operating income (loss) | (5) | (4) | (3) | (3) | 0 | 0 | |
| Operating loss: | (6) | (2) | (1) | (0) | (1) | (1) | |
| Nonoperating expense | (1) | (1) | (0) | (0) | (0) | (0) | |
| Other nonoperating income | 0 | 0 | 0 | 0 | |||
| Interest and debt expense | (0) | (0) | (0) | 0 | 0 | ||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 0 | 0 | 0 | (0) | (0) | ||
| Loss from continuing operations before income taxes: | (7) | (2) | (1) | (1) | (1) | (2) | |
| Income tax expense (benefit) | 0 | 0 | (0) | (0) | |||
| Net loss attributable to parent: | (7) | (2) | (1) | (1) | (1) | (2) | |
| Preferred stock dividends and other adjustments | (0) | (0) | (0) | (0) | (0) | (0) | |
| Net loss available to common stockholders, diluted: | (7) | (2) | (1) | (1) | (1) | (2) | |
Comprehensive Income ($ in millions)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (7) | (2) | (1) | (1) | (1) | (2) | |
| Other comprehensive income (loss) | 0 | (0) | (0) | ||||
| Comprehensive loss: | (7) | (2) | (1) | (1) | (1) | (2) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (0) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (7) | (2) | (1) | (1) | (1) | (2) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.